Cronos (CRON) Stock
Canadian cannabis producer with medical and adult brands. Here's the price, business snapshot, and what's worth knowing about Cronos in June 2026.
Cronos Group Inc (CRON) is a Canadian cannabis company that develops, cultivates and markets cannabis products for medical and adult-use markets. Investors should know it operates through cultivation facilities, consumer brands and international initiatives while seeking scale and product diversification. Cronos has attracted strategic capital and focuses on innovation in categories such as consumer cannabis products and cannabinoid research. With a market capitalisation of about $1.34B, the company sits among mid‑cap cannabis producers and is sensitive to pricing, regulatory change and capital markets conditions. Key considerations include regulatory risk, competitive pressure from domestic and international producers, and the potential for further financing or dilution as it invests to grow. Performance can be volatile and past performance is not indicative of future results. This summary is for educational purposes only and is not personalised investment advice; investors should assess suitability and consider seeking regulated advice.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Cronos Group's stock with a target price of $4.44, indicating growth potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring CRON
Cannabis Reclassification | Schedule III Tax Relief
The DOJ's historic move to reclassify marijuana as a Schedule III drug is removing massive tax burdens and sparking immediate optimism across the cannabis sector. This policy shift unlocks new profitability and operational pathways for medical producers, dispensaries, and pharmaceutical researchers navigating the newly regulated landscape.
Published: April 24, 2026
Explore BasketVice Arbitrage
Get exposure to companies leading the transformation of once-prohibited activities into booming legal industries. These carefully selected stocks represent market leaders capitalizing on shifting regulations in sports betting, cannabis, and more, unlocking tremendous growth potential.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth potential
Product innovation and expanding adult‑use markets could support growth, though outcomes depend on regulation, competition and execution.
Strategic partnerships
Partnerships and investment can help access distribution and capital, but rely on counterparties and favourable market conditions.
Volatile returns
Cannabis stocks are often volatile and sensitive to regulatory shifts and capital needs; investors should expect price swings and possible losses.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
